FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Davis Aaron I.				<u>iT</u>	2. Issuer Name and Ticker or Trading Symbol iTeos Therapeutics, Inc. [ITOS]						(Ch	elationship of the control of the co	able)	Person(s) to Iss		
(Last)						3. Date of Earliest Transaction (Month/Day/Year) 06/11/2024							Officer below)	(give title	Other (s below)	pecify
C/O ITEOS THERAPEUTICS, INC. 321 ARSENAL STREET				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person				
(Street)	TOWN M	IA	02472										Form f Persor		than One Repo	ting
(City)	(8	itate)	(Zip)		Ri	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							l to			
		Tab	le I - Non	-Deriv	vativ	e Se	curities	s Ac	quired, D	isposed o	of, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of Code (Instr. 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4 and			s Form	orm: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	ate,	4. Transactio Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$16.32	06/11/2024			A		24,200		06/11/2025	06/11/2034	Common Stock	24,200	\$0	24,200	D	

Explanation of Responses:

/s/ Adi Osovsky, as Attorney-

in-Fact

06/13/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).